| Literature DB >> 11882004 |
Stephen Connolly1, Colin Bennion, Sarah Botterell, Pamela J Croshaw, Catherine Hallam, Kim Hardy, Paul Hartopp, Clive G Jackson, Sarah J King, Louise Lawrence, Antonio Mete, David Murray, David H Robinson, Gillian M Smith, Linda Stein, Iain Walters, Edward Wells, W John Withnall.
Abstract
Using knowledge of the substrate specificity of cPLA(2) (phospholipases A(2)), a novel series of inhibitors of this enzyme were designed based upon a three point model of inhibitor binding to the enzyme active site comprising a lipophilic anchor, an electrophilic serine "trap", and an acidic binding moiety. The resulting 1,3-diheteroatom-substituted propan-2-ones were evaluated as inhibitors of cPLA(2) in both aggregated bilayer and soluble substrate assays. Systematic variation of the lipophilic, electrophilic, and acidic groups revealed a well-defined structure-activity relationship against the enzyme. Optimization of each group led to compound 22 (AR-C70484XX), which contains a decyloxy lipophilic side chain, a 1,3-diaryloxypropan-2-one moiety as a unique serine trap, and a benzoic acid as the acidic binding group. AR-C70484XX was found to be among the most potent in vitro inhibitors of cPLA(2) described to date being more than 20-fold more active against the isolated enzyme (IC(50) = 0.03 microM) than the standard cPLA(2) inhibitor, arachidonyl trifluoromethyl ketone (AACOCF(3)), and also greater than 10-fold more active than AACOCF(3) against the cellular production of arachidonic acid by HL60 cells (IC(50) = 2.8 microM).Entities:
Mesh:
Substances:
Year: 2002 PMID: 11882004 DOI: 10.1021/jm011050x
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446